ClinicalTrials.gg

Program

QLS32015

A development code.

Its studies are mostly in Multiple Myeloma, led by Qilu Pharmaceutical.

Furthest: phase 3, since Aug 13, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical22 open or runningphase 3since Aug 13, 2025Jun 15, 2023Dec 2027phase 3 · NCT07138209

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 15, 2023First study: phase 1 study in RecurrenceFirst studyNCT05920876 · 100 planned · China
  2. Aug 13, 2025Phase 3 study in RecurrenceNCT07138209 · 228 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in RecurrenceNCT07138209

TargetBeta

CD3E →GPRC5D →read by rule
“QLS32015 is a GPRC5D × CD3 bispecific antibody.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 37
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS4131ruleQilu Pharmaceuticalphase 33
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07138209Recurrence · China3RecruitingDec 2027228
NCT05920876Recurrence · China1RecruitingDec 31, 2024100

How it is read

Names in the registry

  • “QLS32015”, 2 entries

Codes read as this program: QLS32015.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.